Debbie Rigby rounds up the latest in research news
Patients prescribed different device types for reliever and maintenance medications may lead to confusion and suboptimal device use. This literature review suggests that simplifying inhaler regimens by applying the same type of inhaler for concomitant inhaled medications over time minimizes device misuse, leading to improved clinical outcomes and reduced health care use in patients with asthma or COPD.
J Allergy Clin Immunol Pract 2021;9:3033-40.
This post hoc pooled analysis of Symbicort Given as-needed in Mild Asthma (SYGMA) 1 and 2 assessed the efficacy and safety of as-needed BUD-FORM in adolescents. In adolescents with mild asthma, as-needed BUD-FORM was superior to as-needed terbutaline for severe exacerbation reduction, with similar efficacy to BUD maintenance. As-needed BUD-FORM provides an alternative treatment option for adolescents with mild asthma, without needing daily treatment.
J Allergy Clin Immunol Pract 2021;9:3069-77.
A systematic review and meta-analysis of 12 RCTs has concluded that colchicine reduces cardiovascular events and inflammatory markers, hs-CRP and IL-6, in patients with coronary disease compared to controls. At mean follow-up of 22.5 months, the colchicine group had lower risk of major adverse cardiac events, recurrent MI, stroke and hospitalization due to cardiovascular events compared to the control group. There was no difference in all-cause mortality and CV mortality.
British Journal of Clinical Pharmacology 2021.
Data from nearly 100,000 patient records shows concomitant treatment with DOACs and oral glucocorticoids is associated with a short-term rate and risk increase of gastrointestinal bleeding compared with patients only on DOACs. The risk of GI bleeding was increased by 54% for daily doses of oral corticosteroids less than 20mg, and 119% for daily doses 20mg and higher.